Overview

Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management

Status:
Completed

Trial end date:
2018-01-02

Target enrollment:

Participant gender:

Summary

Evaluate the benefits of Kinesia-360™ wearable technology in addition to standard clinical practice on improving Parkinson´s disease motor symptoms, Neupro dosing regimen and adherence to Neupro compared with only standard clinical practice.

Phase:

Phase 4

Details

Lead Sponsor:

UCB Biopharma S.P.R.L.

Treatments:

N 0437
Rotigotine